Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Overview
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Companies Involved in Therapeutics Development
AbbVie Inc
ADT Pharmaceuticals Inc
Celon Pharma SA
Merck & Co Inc
Sunovion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Drug Profiles
ADT-048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
balipodect - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-50003602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCI-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PyP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5461861 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEP-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE10A for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THPP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Dormant Products
cAMP and cAMP Inhibited cGMP 3’,5’ Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by ADT Pharmaceuticals Inc, H1 2020
Pipeline by Celon Pharma SA, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Sunovion Pharmaceuticals Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020